FULC Appoints Josh Lehrer to Board of Directors

Fulcrum Therapeutics, Inc. announced the appointment of Josh Lehrer, M.D., M.Phil., FACC, as an independent director to its Board of Directors. Dr. Lehrer brings over two decades of clinical development experience, including leadership in the development and approval of Oxbryta for sickle cell disease. His expertise in rare disease drug development is expected to be invaluable as Fulcrum advances its lead program, pociredir, for sickle cell disease.